SeeTreat Medical

SeeTreat is pleased to announce that, in partnership with the Image X Institute at the University of Sydney, we have successfully received a three-year NHMRC Development Grant to build an exciting new AI medical device. The Development grant scheme expedites the translation of health and medical research outcomes through to commercialisation within a foreseeable timeframe. The funded research will focus on advancing and investigating a novel AI targeted radiation therapy software device that will personalise radiation therapy targeting to improve patient outcomes for lung, liver, and pancreas cancer patients. SeeTreat’s extensive experience in medical device product development will be invaluable throughout the progress of the grant. SeeTreat founders Professor Paul Keall (also the Director of the Image X Institute) and Dr Trang Nguyen (SeeTreat CEO) are the grant’s Chief Investigators A and B respectively. More information on NHMRC Development Grants can be found via this link: https://lnkd.in/g7_zV5D8

SeeTreat Welcomes New Directors Dr Richard Hausmann, A.Prof. Tee Lim (Radiation Oncologist) and Dr Shane La Bianca (Urologist). SeeTreat, a software medical device company with a vision to ‘turn on the light’ for oncology treatments enabling affordable personalised and precise treatment for every patient, is pleased to announce new Board directors as SeeTreat prepares for commercial release of its first products to clinics. We welcome Dr Richard Hausmann, Associate Professor Tee Lim and Dr Shane La Bianca to our Board from October 2024. They will join existing executive Board members Dr Trang Nguyen (CEO and Co-Founder), Professor Paul Keall (Co-Founder) and Antonia Dalton (Chief Strategy Officer). More information about our new Directors here: https://lnkd.in/gQryPzPG

We are very excited to announce that ICON Group (Icon Cancer Centre - Australia & New Zealand, Icon Group ) will be the first to partner with SeeTreat to lead innovation in precision radiation therapy treatment. SeeTreat is a unique Australian medical software start-up who is solving real clinical problems in radiotherapy through software solutions that are high quality, efficient and both patient and user centric. This collaboration will see Icon trial SeeTreat’s software innovation, Dose Review, at select cancer centres in Australia. Dose Review accurately measures a patient’s radiotherapy dose daily to and ensure patients receive the right treatment at the right time for their anatomy, which can change during treatment and over time. Read the full story: https://lnkd.in/dzh7BB-c

Lumonus and SeeTreat Medical are pleased to announce their partnership to improve personalisation and precision in radiotherapy treatment in the USA in 2025.   Combining Lumonus AI Product with SeeTreat’s software solutions means ALL patients can be assured of receiving radiotherapy to the right place at the right time despite changes in tumour size or shape and anatomy over the course of treatment.  Our combined software solutions are designed to be user centric, efficient and accessible to all.  The partners estimate that the combined platform will enable assessment of every patient for planning adaptation, whilst saving clinical teams up to 5 hours each time. Our teams are excited to be joining forces to innovate for the benefit of millions of cancer patients each year.

SeeTreat has raised seed funding of $700k! This significant milestone will support development and commercialisation of our products in Australia, the USA and Europe in early 2025. Our first products will improve patient outcomes by personalising and improving precision in radiotherapy treatment. Watch this space! For more information on SeeTreat, see our website: https://lnkd.in/gkbyjweN

Congratulations to Paul Keall, one of SeeTreat's founders, for being made an honorary member of the European Society for Radiotherapy and Oncology (ESTRO).

Congratulations to our co-founder and Director Paul Keall on his ESTRO honorary member award for lifetime scientific contributions to radiation oncology! We are so proud of you Paul Keall. Now let's make access to radiation oncology equitable for all!

We are hiring: https://lnkd.in/g5sARNZM